4.51
-0.19(-4.04%)
Currency In USD
| Previous Close | 4.7 |
| Open | 4.8 |
| Day High | 4.8 |
| Day Low | 4.48 |
| 52-Week High | 16.11 |
| 52-Week Low | 3.55 |
| Volume | 126,833 |
| Average Volume | 232,708 |
| Market Cap | 204.28M |
| PE | -7.05 |
| EPS | -0.64 |
| Moving Average 50 Days | 4.47 |
| Moving Average 200 Days | 7.97 |
| Change | -0.19 |
If you invested $1000 in Y-mAbs Therapeutics, Inc. (YMAB) since IPO date, it would be worth $187.92 as of July 01, 2025 at a share price of $4.51. Whereas If you bought $1000 worth of Y-mAbs Therapeutics, Inc. (YMAB) shares 5 years ago, it would be worth $107.18 as of July 01, 2025 at a share price of $4.51.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Y-mAbs Hosts Virtual Radiopharmaceutical R&D Update Highlighting Clinical Progress and Expanded Pipeline
GlobeNewswire Inc.
May 28, 2025 10:35 AM GMT
Company’s Part A data readout from first-in-human Phase 1 Trial 1001 in patients with recurrent or refractory metastatic solid tumors known to express GD2, validates GD2-SADA as safe, tolerable and able to achieve targeted in vivo conjugation of 177L
Y-mAbs Presents GD2-SADA PRIT Trial in Progress Poster at the Advances in Neuroblastoma Research Meeting
GlobeNewswire Inc.
May 26, 2025 2:00 PM GMT
PRINCETON, N.J., May 26, 2025 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel radioimmunotherapy and an
Y-mAbs to Host Virtual Radiopharmaceutical R&D Update on May 28, 2025
GlobeNewswire Inc.
May 13, 2025 11:05 AM GMT
PRINCETON, N.J., May 13, 2025 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel radioimmunotherapy and an